Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4756 AL 4770

Cholesterol, statins, and dementia: what the cardiologist should know

Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS.

Clin Cardiol. 2015 Apr;38(4):243-50. doi: 10.1002/clc.22361. Epub 2015 Apr 13.

Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio

Cselényi Z, Farde L.

J Cereb Blood Flow Metab. 2015 Sep;35(9):1485-93. doi: 10.1038/jcbfm.2015.66. Epub 2015 Apr 15.

The economic impact of moderate stage Alzheimer's disease in Italy: evidence from the UP-TECH randomized trial

Chiatti C, Furneri G, Rimland JM, Demma F, Bonfranceschi F, Cassetta L, Masera F, Cherubini A, Corsonello A, Lattanzio F; UP-TECH research group.

Int Psychogeriatr. 2015 Sep;27(9):1563-72. doi: 10.1017/S104161021500040X. Epub 2015 Apr 15.

Neuroprotective effects of geniposide on Alzheimer's disease pathology

Liu W, Li G, Hölscher C, Li L.

Rev Neurosci. 2015;26(4):371-83. doi: 10.1515/revneuro-2015-0005.

Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials

Jiang J, Jiang H.

Neurol Sci. 2015 Sep;36(9):1633-41. doi: 10.1007/s10072-015-2221-2. Epub 2015 Apr 22.

Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease

Plosker GL.

Drugs. 2015 May;75(8):887-97. doi: 10.1007/s40265-015-0400-3.

Rodent models for Alzheimer's disease drug discovery

Puzzo D, Gulisano W, Palmeri A, Arancio O.

Expert Opin Drug Discov. 2015 Jul;10(7):703-11. doi: 10.1517/17460441.2015.1041913. Epub 2015 Apr 30.

Nanomedicine for the treatment of Alzheimer's disease

Gregori M, Masserini M, Mancini S.

Nanomedicine (Lond). 2015;10(7):1203-18. doi: 10.2217/nnm.14.206.

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

Butchart J, Brook L, Hopkins V, Teeling J, Püntener U, Culliford D, Sharples R, Sharif S, McFarlane B, Raybould R, Thomas R, Passmore P, Perry VH, Holmes C.

Neurology. 2015 May 26;84(21):2161-8. doi: 10.1212/WNL.0000000000001617. Epub 2015 May 1.

Outpatient treatment of sleep disorders in Alzheimer patients

Scoralick FM, Camargos EF, Freitas MP, Nóbrega OT.

Einstein (Sao Paulo). 2015 Jul-Sep;13(3):430-4. doi: 10.1590/S1679-45082015RW3021. Epub 2015 May 1.

Masitinib for the treatment of mild to moderate Alzheimer's disease

Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, Lazarowski A, Marin M, Olloquequi J, Auladell C, Camins A.

Expert Rev Neurother. 2015 Jun;15(6):587-96. doi: 10.1586/14737175.2015.1045419. Epub 2015 May 11.

Drug repositioning in Alzheimer's disease

Corbett A, Williams G, Ballard C.

Front Biosci (Schol Ed). 2015 Jun 1;7(1):184-8. doi: 10.2741/S432.

Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer's Disease

Faldu KG, Shah JS, Patel SS.

Recent Pat Antiinfect Drug Discov. 2015;10(2):76-83. doi: 10.2174/1574891x10666150509193236.

Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein

Folch J, Ettcheto M, Petrov D, Abad S, Pedrós I, Marin M, Olloquequi J, Camins A.

Neurologia (Engl Ed). 2018 Jan-Feb;33(1):47-58. doi: 10.1016/j.nrl.2015.03.012. Epub 2015 May 11.

Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer's Disease

Ajith TA, Padmajanair G.

Curr Aging Sci. 2015;8(3):235-40. doi: 10.2174/187460980803151027115147.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias